This study was performed to gain insights into novel therapeutic approaches for the treatment of autoimmune myocarditis.
R ecent studies revealed an immunomodulatory property of the vagus nerve referred to as the cholinergic antiinflammatory pathway. 1 The efferent arm of the vagus nerve exerts antiinflammatory effects through the ␣7 nicotinic acetylcholine receptor (␣7-nAChR), which is expressed not only by central nervous system-specific cells but also by immune cells such as macrophages and CD4 ϩ T cells. [2] [3] [4] Acetylcholine, the principal neurotransmitter of the cholinergic system, is the endogenous agonist of ␣7-nAChR and is synthesized by both nervous and immune cells. 5 Signaling of acetylcholine through ␣7-nAChR has been shown to attenuate the production of tumor necrosis factor (TNF)-␣, inter-leukin (IL)-1␤, IL-6, and IL-18 by human macrophages. 6 However, it has been shown that nicotine, as a specific agonist of ␣7-nAChR, is more efficient than acetylcholine at inhibiting the production of proinflammatory cytokines by macrophages. 7 The antiinflammatory potential of ␣7-nAChR is mediated through inhibition of the transcription factor nuclear factor-B and involvement of the JAK/STAT3 (Janus kinase/signal transducer and activator of transcription 3) signaling cascade. 8 The positive effects of ␣7-nAChR agonists have been studied in vivo in various disease models.
For example, nicotine reduced TNF-␣ and IL-6 production by peritoneal macrophages in sepsis and reduced inflamma-tory cell infiltration in a carrageenan air pouch model. 9, 10 GTS-21, an agonist of ␣7-nAChR, reduced serum TNF-␣ and improved survival rate in murine endotoxemia. 11 In addition, transcutaneous vagus nerve stimulation has been shown to reduce serum levels of high-mobility group protein B1 (HMGB1) and to improve survival in sepsis. 12 Because acetylcholine is the naturally occurring ligand of ␣7-nAChR, it is conceivable that acetylcholinesterase activity may regulate inflammatory processes. Therefore, acetylcholine has been targeted indirectly by specific inhibition of acetylcholinesterase. Indeed, acetylcholinesterase inhibitors such as neostigmine suppressed the production of circulating TNF-␣, IL-1␤, and Il-6 and increased survival rate in murine sepsis. 9 Another study showed that galantamine, another acetylcholinesterase inhibitor, decreases serum TNF-␣ through vagus nerve signaling and protects against lethality in murine endotoxemia. 13 Although many studies exist that show the protective effect of vagus nerve stimulation in inflammatory diseases, only a few attempts have been made to study the beneficial role of the vagus nerve in heart failure. Francis et al 14 showed that vagus nerve innervation of the heart plays an important role in the regulation of proinflammatory cytokines early after acute myocardial infarction. In addition, the cardioprotective effect of vagus nerve stimulation has been shown in models of chronic heart failure and myocardial ischemia/reperfusion injury. [15] [16] [17] The effect of vagus nerve stimulation on myocarditis has not yet been investigated. Recently, we showed that immunization of mice with murine cardiac troponin I (TnI) induced an autoimmune response that led to severe inflammation in the myocardium and increased proinflammatory cytokine levels, followed by heart failure. 18 We hypothesized that chemical vagus nerve stimulation through activation of ␣7-nAChR may attenuate the proinflammatory processes caused by TnI immunization. Thus, in the present study, we investigated whether nicotine administration attenuates inflammation in experimental autoimmune myocarditis.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice
Female A/J mice (5 to 6 weeks of age) obtained from Harlan Winkelmann GmbH (Borchen, Germany) were used. Mice were maintained in the animal facility at the University of Heidelberg according to standard protocols for animal care. The present experimental model was approved by the Animal Care and Use Committee of the University of Heidelberg.
Preparation of Recombinant Murine Cardiac TnI
The murine cardiac troponin subunit TnI was expressed in Escherichia coli and purified as described previously. 19 In addition to purification via ion exchange chromatography, TnI was applied to a cardiac troponin C affinity column as a second purification step. 20 Isolated TnI fractions were dialyzed against 1 mmol/L HCl, then lyophilized and stored at Ϫ80°C until further use.
Immunization With TnI and Pharmacological Treatment
Mice were immunized twice by subcutaneous injection of 100 L of an emulsion that contained 120 g of TnI in supplemented complete Freund's adjuvant (Sigma, St Louis, MO; day 0 and day 7). (Ϫ)-Nicotine hydrogen tartrate salt (Sigma) and neostigmine bromide (Sigma) were dissolved in water for oral administration. Intraperitoneally injected nicotine was dissolved in PBS. We compared 7 groups with different pharmacological treatment patterns (Table 1) . Immunized mice with no pharmacological treatment were recognized as positive controls. Negative controls were immunized with complete Freund's adjuvant and PBS only.
In a subsequent experiment, we injected recombinant murine IL-6 (PeproTech, Hamburg, Germany), in a concentration of 25 ng per 10 g of body weight, intraperitoneally every 3 days until day 21, concomitant with nicotine (125 mg/L on day Ϫ3 to day 21). IL-6 was dissolved in PBS. Animals in all groups were euthanized 21 days after initial immunization for further examinations.
Cardiac TnI-Dependent Cytokine Production by Splenocytes
For in vitro cytokine production, splenocytes were cultured at 5ϫ10 6 per well (24-well plates) in RPMI 1640 complete medium in the presence of 30 g/mL of either TnI or medium alone for 48 hours. Supernatant was collected, separated into aliquots, and frozen at Ϫ20°C. Cytokines (IL-2, IL-6, IL-10, IL-17, IL-13, interferon-␥ [IFN-␥], and TNF-␣) were measured by DuoSet ELISA development systems (R&D Systems, Wiesbaden-Nordenstadt, Germany), according to the manufacturer's instructions.
Histopathologic Evaluation
For the histopathologic evaluation of myocardium, mice were euthanized on day 21 after immunization with TnI. Sections of 5-m thickness were cut and stained with hematoxylin and eosin to 
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determine the level of inflammation and with Masson's trichrome to detect collagen deposition. The extent of inflammation and fibrosis was quantified in a blinded manner by 2 independent investigators using light microscopy, according to the following scoring system: grade 0, no inflammation; grade 1, cardiac infiltration in up to 20% of the cardiac sections; grade 2, 21% to 40%; grade 3, 41% to 60%; grade 4, 61% to 80%; and grade 5, Ͼ80%.
Immunoenzyme Staining
The following primary antibodies were used: rabbit polyclonal antibody IgG anti-CD3 1/200 (clone: SP7; NeoMarkers, Fremont, CA), mouse monoclonal antibody IgG1 anti-CD4 1/20 (clone: mAb51312; Abcam, Cambridge, United Kingdom), rat monoclonal antibody IgG2b anti-CD8 1/50 (clone: YTS169.4; Abcam), mouse monoclonal antibody IgG2a, anti-CD45R0 1/800 (clone: UCHL1; DakoCytomation, Glostrup, Denmark), and mouse monoclonal antibody IgG1 anti-CD68 1/8000 (clone: KP1; DakoCytomation). Isotype-and concentration-matched control antibodies (DakoCytomation) served as negative controls. Immunoenzyme staining was performed on 2-m sections of formalin-fixed, paraffin-embedded murine hearts. Heat-induced antigen retrieval was achieved by incubating the slides in a pressure cooker for 5 minutes in citrate buffer, pH 6.1. Slides were further processed by the standard avidin-biotin complex anti-alkaline phosphatase procedure (CD3, CD45R0, and CD68) or the standard avidin-biotin complex antihorseradish peroxidase procedure (CD4 and CD8) according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA). The primary antibody was added for 1 hour at room temperature (CD4 and CD8) or overnight at 4°C (others). Species-specific biotinylated antibodies (1/100; Dako) were used as a secondary reagent (30 minutes at room temperature). Naphthol AS-BI phosphate (Sigma) with new fuchsin (Merck, Darmstadt, Germany) served as the substrate for alkaline phosphatase. 3,3Ј-Diaminobenzidine (Merck) served as the substrate for peroxidase. Five-micrometer cryosections of fresh-frozen murine hearts were used for CD8 staining after fixation with ice-cold acetone for 20 minutes. Slides were processed further as described above.
Echocardiography
Transthoracic echocardiography was performed as described previously. 17 The investigator who conducted the echocardiography was unaware of the treatment status of the respective mice.
RNA Protection Assay
Total RNA was extracted from heart tissue with the RNeasy Midi kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The mCR-5 cytokine receptor multiprobe template set (BD Biosciences-Pharmingen, Heidelberg, Germany) was used to measure mouse mRNAs encoding CCR1, CCR2, CCR1b, CCR3, CCR4, and CCR5. The mCK-5c multiprobe template set (BD Biosciences-Pharmingen) was used to measure mouse mRNAs encoding lymphotactin, RANTES, macrophage inflammatory protein (MIP)-1␤, MIP-1␣, MIP-2, interferon-inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), T-cell activation gene 3 (TCA-3), and eotaxin. Measurement was performed according to the manufacturer's guidelines.
Quantitative Polymerase Chain Reaction
Total RNA was extracted from heart tissue with the RNeasy Midi kit according to the manufacturer's protocol. cDNA synthesis (iScript cDNA Synthesis Kit, Bio-Rad, München, Germany) was performed with 1 g of RNA according to the manufacturer's protocol. For quantitative polymerase chain reaction, 1 L of cDNA was used. After an initial denaturation of 95°C for 30 seconds, 40 cycles were performed that consisted of denaturation at 95°C for 5 seconds and annealing at 60°C for 10 seconds. We used the primer sequences detailed in Table 2 for quantification of transcript levels. Quantification was performed with a Fast Eva-Green Kit (Bio-Rad) according to the manufacturer's instructions.
Western Blotting
The following primary antibodies were used for Western blotting: rabbit polyclonal anti-MMP-2 (Dianova, Hamburg, Germany), rabbit polyclonal anti-MMP-9, rabbit monoclonal pSTAT3 (New England BioLabs, Frankfurt, Germany), rabbit monoclonal anti-MMP-14 (Abcam, Berlin, Germany), rabbit polyclonal anti-natriuretic peptide precursor A (BioCat, Heidelberg, Germany), and goat polyclonal anti-TIMP-1 and anti-osteopontin (R&D Systems, Wiesbaden, Germany). Western blot was performed with total protein extracts derived from hearts harvested on day 21. Five to 30 g of protein extract per lane was separated by SDS-PAGE with 10% polyacrylamide and transferred onto a PVDF transfer membrane (Millipore Immobilon-P; Millipore, Schwalbach, Germany). The membrane was first blocked for 1 hour at room temperature with 5% nonfat dry milk powder in TBST (TBS/0.05% Tween 20), followed by antibody incubation overnight at 4°C dissolved in 5% bovine serum albumin. The blots were then incubated with a peroxidase-linked secondary IgG antibody for 1 hour at room temperature (anti-rabbit and anti-mouse antibody from GE Healthcare, München, Germany, or anti-goat antibody from Dianova). The secondary antibody was diluted in blocking solution 1:10 000 for anti-rabbit and anti-mouse or 1:20 000 for anti-goat antibody. Peroxidase-substrate reaction was performed with the ECL protein biotinylation module according to the manufacturer's guidelines (GE Healthcare, Buckinghamshire, United Kingdom).
Flow Cytometry
The following antibodies were used for flow cytometry: PE-anti-TNF-␣, PE-anti-IL-6 PE-anti-IFN-␥, Alexa488-anti-IL17, PE-anti-CD3, and FITC-anti-CD3 (all from BD Pharmingen); PECy5-antiCD4, PECy5-anti-CD8, and PECy5-anti-B220, APC-anti-CD11c (all from Miltenyi Biotec, Gladbach, Germany); and APC-anti-CD11b (eBioscience, Frankfurt, Germany). Total splenocytes from 10 mice in each group were isolated from TnI-immunized mice and cultured at 5ϫ10 6 per well (24-well plates) in RPMI 1640 complete medium in the presence of TnI 30 g/mL for 38 hours (37°C, 5% CO 2 ). Five hours before they were harvested, cells were treated with PMA/ionomycin (PMA 50 ng/mL, ionomycin 1000 ng/mL) and GolgiPlug (1:1000, BD Pharmingen). After they were harvested, cells were surface stained with combinations of fluorochromelabeled antibodies according to standard procedures, including a blocking step with anti-CD-16/32 Fc-blocking reagent (BD Pharmingen). In a fixation and permeabilization step (Fix-Perm, BD Pharmingen), cells were preincubated with normal rat serum (eBioscience) before intracellular staining with respective anti-cytokine antibodies. Expression of surface receptors and cytokines was quantified on a double-laser (488 and 637 nm), 5-color FACScan flow cytometer (BD Biosciences, upgraded by Cytek).
Statistical Analysis
Results are expressed as mean ϮSEM. Data were analyzed with the Kruskal-Wallis test followed by the Mann-Whitney U test to explore the significance between treatment groups. PϽ0.05 was considered 
Results
Nicotine but Not Neostigmine Reduces Inflammatory Infiltrate and Fibrosis in TnI-Immunized Mice
TnI-immunized mice with no pharmacological treatment had extensive cellular infiltrate and fibrosis within the myocardium, as shown by staining with hematoxylin and eosin and Masson's trichrome (histoscore 1.8Ϯ0.3; fibrosis score: 1.8Ϯ0.4) 21 days after initial immunization. In contrast, TnI-immunized mice that were exposed to high and low doses of nicotine (125 and 12.5 mg/L, respectively) in the drinking water until day 21 showed significantly lower inflammation and fibrosis (histoscore 0.4Ϯ0.2 and 0.6Ϯ0.2; fibrosis score 0.5Ϯ0.3 and 0.6Ϯ0.2, respectively; Figure 1 ). Figure 2A shows representative hematoxylin-and-eosin-and Masson's trichrome-stained heart sections of TnI-immunized mice with (TnI/nicotine 125 mg/L) and without (TnI/Ϫ) high-dose nicotine treatment until day 21. In both treatment groups, immunohistological stainings on day 21 revealed similar composition of the cellular infiltrate. It consisted primarily of CD4 ϩ CD45RO ϩ T cells and CD68 ϩ macrophages ( Figure 2B ). To study the effect of short-term expo-sure to nicotine, immunized mice received nicotine in the drinking water for only 3 days after initial immunization. Histological evaluation after 21 days showed significantly decreased inflammation with high-dose nicotine (histoscore 0.5Ϯ0.2; fibrosis score 0.5Ϯ0.3), whereas low-dose nicotine had no significant effect (histoscore 1.2Ϯ0.4; fibrosis score: 1Ϯ0.4; Figure 1 ). Intraperitoneal administration of nicotine for a total of 3 days after immunization showed a tendency to decrease inflammation, although not significantly (histoscore 0.8Ϯ0.3; fibrosis score 0.7Ϯ0.3; Figure 1 ). Neither intraperitoneal treatment with the acetylcholinesterase inhibitor neostigmine nor neostigmine exposure through the drinking water altered the inflammatory response within the myocardium (data not shown).
Nicotine Reduces TNF-␣ and IL-6 Production
In vitro cytokine production by TnI-restimulated splenocytes was measured in all groups. We observed significantly lower levels of the proinflammatory cytokines TNF-␣ and IL-6 in all groups that received nicotine in the drinking water, whereas no significant difference was found in the production of IL-10, IL-13, IL-2, IL-17, or IFN-␥ in the corresponding groups ( Figures 3A through 3D) . Intraperitoneal administration of nicotine did not reveal any significant alterations in cytokine production ( Figure 3E ).
Intracellular staining of cytokine-producing cells in immunized mice revealed that both TNF-␣ and IL-6 were produced by all splenic subpopulations tested when restimulated with TnI in vitro (Figure 4 ). In control mice without nicotine treatment, total TNF-␣ was produced primarily by B cells (B220 ϩ ) and T cells (CD3 ϩ ; 48% versus 45%; Figure 4A ), whereas only a minor amount of TNF-␣ was derived from macrophages and dendritic cells (6% and 1%, respectively; Figure 4A ). In contrast, the majority of total IL-6 was produced by CD3 ϩ CD4 ϩ (72%) and CD3 ϩ CD8 ϩ (20%) T cells, whereas B-cell-mediated total IL-6 production was only 7% ( Figure 4C) . Given that the total amount of TNF-␣ and IL-6 production by splenocytes was significantly reduced in nicotine-treated TnIimmunized mice (from 176Ϯ75 to 38Ϯ21 and from 486Ϯ69 to 287Ϯ70 pg/mL, respectively; Figure 3 ), the proportions of TNF-␣-or IL-6 -producing populations ( Figures 4B and 4D ) remained largely constant. Because the majority of spleen tissue consisted of B cells (46%) and T cells (37%) and only a very few macrophages and dendritic cells (macrophages 6%, dendritic cells 1%), we calculated the relative percentage of TNF-␣ and IL-6 produced by the different types of splenocytes ( Figures 4E  through 4G ).
We also investigated whether IFN-␥ and IL-17 production by CD4 ϩ cells was affected by nicotine administration. To address this question, we performed fluorescence-activated cell sorter analysis with intracellular staining for IFN-␥ and IL-17 in isolated CD3 ϩ CD4 ϩ splenocytes. Neither IFN-␥ nor IL-17 production by CD3 ϩ CD4 ϩ cells was affected by highdose nicotine treatment (IFN-␥: TnI/Ϫ 65% versus TnI/nicotine 67%; IL-17: TnI/Ϫ 85% versus TnI/nicotine 89%).
TnI-Induced STAT3 Activation Is Inhibited by Nicotine
The IL-6 -dependent JAK2/STAT3 signaling pathway plays a critical role in cytokine signal transduction, and recent studies have revealed a potential role of this pathway in the pathogenesis of myocarditis. We observed increased phosphorylated STAT3 (pSTAT3) protein levels in TnIimmunized mice, as shown by Western blot. Next, we explored whether nicotine affected STAT3 activation in our model. We found that high-dose (125 mg/L) oral nicotine treatment until day 21 reduced pSTAT3 protein levels in immunized mice ( Figure 5 ).
Nicotine Reduces Transcript Levels of CCR1, CCR2, and CCR5
We examined mRNA expression of chemokines and the chemokine receptors CCR1, CCR1b, CCR2, CCR3, and CCR5 in the myocardium via RNAse protection assay (Figure 6) . In TnI-immunized mice with no pharmacological treatment, we detected myocardial mRNA of CCR1, CCR5, and CCR2. Although intraperitoneal nicotine treatment in immunized mice did not change transcript levels of these chemokine receptors, nicotine exposure in the drinking water (125 mg/L until day 21) significantly reduced myocardial transcript levels of CCR1, CCR5, and CCR2 ( Figure 6B ). Furthermore, we detected decreased chemokine levels (MCP-1, MIP-1␤, and RANTES) in these mice ( Figure 6A ).
Nicotine Treatment Results in Reduced Transcript Levels of Natriuretic Peptides and Extracellular Matrix Regulatory Proteins
To elucidate the effect of nicotine on extracellular matrix metalloproteinases and on genes that are commonly involved in heart failure, we performed quantitative polymerase chain Figure 7A ). Furthermore, there was a reduction of MMP-2 (nicotine 3.0Ϯ0.5 versus control 5.4Ϯ1.1; Figure  7A ) and MMP-9 (nicotine 2.4Ϯ0.3 versus control 11.3Ϯ3.5; Figure 7A ). We did not observe any alterations in transcript levels of natriuretic peptide precursor A. Figure 7B shows corresponding myocardial protein levels at day 21 after initial immunization in nicotine-treated mice and control mice, evaluated by Western blot. Western blot analysis for NPPB could not be performed because we were not able to obtain a specific antibody against mouse NPPB commercially.
The Antiinflammatory Effect of Nicotine Is Restored by Concomitant IL-6 Administration
STAT3 activity is an IL-6 -driven mechanism. Given the significant downregulation of IL-6 and pSTAT3 in mice treated with nicotine (Figures 3 and 5 ), we administered recombinant murine IL-6 protein concomitantly with nicotine in TnI-immunized mice. Immunized mice treated with both high-dose nicotine and IL-6 up to day 21 showed a significant increase in myocardial inflammation and fibrosis compared with immunized mice treated with high-dose nicotine only (hematoxylin and eosin: TnI/nicotine/IL-6 1.9Ϯ0.6 versus TnI/nicotine 0.6Ϯ0.3. PϽ0.05; Masson's trichrome: TnI/ nicotine/IL-6 1.7Ϯ0.5 versus TnI/nicotine 0.6Ϯ0.3. PϽ0.05; Figures 8A and 8B) .
Echocardiographic analysis revealed significant alterations in left ventricular end-systolic and end-diastolic diameters in the group treated with high-dose nicotine until day 21 compared with the TnI-immunized group with and without additional IL-6 administration (left ventricular end-diastolic diameter: TnI/Ϫ 3.2Ϯ0. 1 Figure 8C ). Fractional shortening showed a trend toward improvement in nicotine-treated mice compared with control mice (TnI/Ϫ 39.1Ϯ5.1% versus TnI/nicotine 47.8Ϯ2.0% versus TnI/ nicotine/IL-6 46.7Ϯ1.5%; Figure 8C ). Heart rates were within normal limits and did not show any significant alterations among the different treatment groups (TnI/Ϫ 448Ϯ11 bpm versus TnI/nicotine 492Ϯ33 bpm versus TnI/ nicotine/IL-6 523Ϯ37 bpm; Figure 8C ).
Discussion
The purpose of the present study was to investigate the therapeutic use of chemical vagus nerve stimulation in autoimmune myocarditis. Induction of experimental autoimmune myocarditis was performed through immunization of 
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mice with cardiac TnI, which leads to severe inflammation in the myocardium followed by fibrosis and heart failure. 21 Our data show for the first time that cholinergic stimulation of the vagus nerve significantly reduces the inflammatory response on TnI immunization. Nicotine treatment decreased inflammation and fibrosis in the myocardium. Moreover, levels of the proinflammatory cytokines IL-6 and TNF-␣ were reduced in mice treated with oral nicotine. Furthermore, myocardial mRNA expression of chemokines (MCP-1, MIP-1␤, and RANTES) and the chemokine receptors CCR1, CCR2, and CCR5 was reduced in nicotine-treated mice. These chemokines are released by many different cell types. Corresponding receptors are typically expressed on different immune cells (such as T cells, B cells, basophils, monocytes/ macrophages, dendritic cells, and others) and serve to guide cells of both the innate immune system and the adaptive immune system to inflammatory areas. 22, 23 In addition, we showed that the antiinflammatory effect of nicotine in our model of TnI-induced autoimmune myocarditis in part involved the STAT3 signaling pathway.
We previously examined the important role of chemokines and chemokine receptors in the pathogenesis of autoimmune myocarditis. 21 Transcript levels of CCR1, CCR2, and CCR5 but not CCR1b, CCR3, and CCR4 were increased significantly in myosin-induced myocarditis. Knockout of CCR2 or CCR5 or the blocking of MCP-1 with monoclonal antibodies led to reduced severity of cardiac myosin-induced myocarditis. In accordance with these previous findings, here, we showed that nicotine stimulation lowers not only myocardial mRNA expression of the chemokines MCP-1, MIP-1␤, and RANTES but also transcript levels of CCR1, CCR2, and CCR5, which leads to a milder outcome of TnI-induced myocarditis. The nicotine-dependent downregulation of MCP-1 has been shown previously in a rat model of spinal cord injury. 24 In a murine model of autoimmune myocarditis, elevated levels of MCP-1 correlated with enhanced IL-6 and TNF-␣ mRNA. 25 The present results are consistent with various studies in which the cholinergic pathway has been shown to exert antiinflammatory effects on several diseases, such as rheumatoid arthritis, 26 inflammatory bowel disease, 27 and sepsis. 28 Although the physiology of the cholinergic antiinflammatory pathway is not yet completely understood, it is well established that ␣7-nAChR plays a central role in triggering proinflammatory cytokine release. 29 Here, we used the ␣7-nAChR agonist nicotine, which has been shown to exert antiinflammatory effects in mouse models of septic peritonitis and collagen-induced arthritis. 30, 31 We used 2 different nicotine concentrations (high,125 mg/L; low,12.5 mg/L) for oral administration, both of which resulted in decreased inflammatory infiltrate when administered chronically throughout the time of the experiment. Of note, low-dose nicotine (in contrast to high-dose nicotine) failed to be effective when administered for up to 3 days after immunization, which indicates a dose-dependent effect of nicotine treatment. These data show that short-term activation of ␣7-nAChR is sufficient to halt the progression of myocarditis when nicotine concentration is high enough. This finding is supported by a recent publication by Hofer and colleagues 9 in which sepsis in mice was induced by cecal ligation and puncture. Immediate intraperitoneal nicotine injection for 3 days reduced lethality and downregulated the circulating proinflammatory cytokines TNF-␣ and IL-6. The downregulation of these cytokines correlates with our results, in which we found reduced levels of TNF-␣ and IL-6 production by TnI-stimulated splenocytes. In fact, there is much evidence suggesting the potential role of TNF-␣ and IL-6 in the pathogenesis of myocarditis. For example, patients with infectious and viral myocarditis have elevated levels of TNF-␣ protein and mRNA in myocardial tissue. [32] [33] [34] TNF-␣ plays a major role in the progression of myocarditis, given that targeted myocardial overexpression of TNF-␣ leads to severe myocarditis, cardiomegaly, and progressive myocardial fibrosis. [35] [36] [37] In addition, exogenously administered TNF-␣ increases myocarditis, and inhibition of TNF-␣ with antibodies or soluble receptors attenuates viral myocarditis. 38, 39 As for IL-6, it has been shown that its constitutive overexpression promotes viral myocarditis. 40 Pharmacological inhibition of IL-6 has beneficial effects on the development of virus-induced encephalomyocarditis. 41 It has also been shown that IL-6 deficiency protects against development of myosin-induced myocarditis in mice. 42 In the present study, we showed that chronic nicotine stimulation led to reduced secretion of TNF-␣ and IL-6 by isolated TnI-stimulated splenocytes. This downregulation correlated with decreased myocardial inflammation and fibrosis. This antiinflammatory effect of nicotine was restored by concomitant IL-6 administration.
Nicotine treatment not only reduced inflammation and fibrosis in the myocardium but also significantly prevented alterations in left ventricular end-systolic and end-diastolic diameter and showed a trend to improved fractional shortening. Furthermore, we investigated whether nicotine stimulation had an effect on extracellular MMPs and other proteins that are typically involved in heart failure. Cardiac extracellular matrix remodeling during heart failure is importantly dependent on the activity of extracellular MMPs. 43 Here, we showed that nicotine treatment reduced transcript and protein levels of the myocardial MMP MMP-14, and the proteins NPPB and osteopontin. Interestingly, we also observed a decrease in TIMP-1, a tissue inhibitor of metalloproteinases, in nicotine-treated mice. This may be compensatory because of increased metalloproteinase activity in control mice with severe inflammation and fibrosis.
We further investigated potential effects of the acetylcholinesterase inhibitor neostigmine to attenuate myocarditis. In addition to its antiinflammatory property, Hofer and colleagues 9 showed a therapeutic effect of neostigmine on experimental sepsis, which was as effective as nicotine. Freeling and colleagues 44 indicated the downregulation of TNF-␣ in neostigmine-treated rats in a model of cardiac pressure overload. Despite these reports, the beneficial effect of neostigmine treatment on inflammatory diseases must be viewed critically. For instance, Akinci and colleagues 44a could not prevent histopathologic organ injury in a murine model of endotoxemia by treating animals with intraperitoneal neostigmine injection at low doses (0.1 mg/kg), although the treatment pattern and concentration of the drug were the same as described by Hofer and colleagues. 9 At higher doses (0.3 mg/kg), organ injury could be prevented, but this was accompanied by a high incidence of early mortality, probably because of nonspecific parasympathetic activity, such as bradycardia. 45, 46 In the present study, both oral and intraperitoneal treatment with neostigmine failed to reduce inflammation and fibrosis in TnI-immunized mice. In fact, we observed a high incidence of mortality within 21 days after immunization in mice treated with oral neostigmine (Ϸ50%; data not shown). Neostigmine is believed to block peripheral ␣7-nAChR, thereby inhibiting ligand/receptor interaction and thus suppressing any downstream processes. Zheng and colleagues 47 showed that neostigmine blocks neuronal nAChRs through interaction with the acetylcholine-binding sites of these receptors. Of note, in the present study, we administered neostigmine peripherally. In this context, Yoon and colleagues 48, 49 had shown that centrally administered neostigmine produces a significant peripheral antiinflammatory effect through activation of spinal muscarinic type 2 receptors (M2R). Other studies have shown that peripheral M2Rs, in contrast to central M2Rs, are not involved in the regulation of inflammatory responses or its inhibition by the cholinergic antiinflammatory pathway. 50 Binding of peripheral neostigmine to central M2R is unlikely, because neostigmine does not cross the blood-brain barrier. To the best of our knowledge, in the periphery, ␣7-nAChR is the only acetylcholine receptor to trigger vagal antiinflammatory output. The downstream pathways after ligand binding to ␣7-nAChR are poorly understood. The JAK-STAT pathway recently has been shown to have an integral role in controlling the acute phase of viral myocarditis. 51 We showed that pSTAT3 in cardiac tissue was upregulated in our model of TnI-induced autoimmune myocarditis and that oral nicotine treatment reduced protein levels of pSTAT3. The activation of STAT3 facilitates its dimerization, nuclear translocation, and the activation of gene transcription, which results in a proinflammatory response by upregulation of chemokines/cytokines, including MCP-1. 52, 53 In the present study, we detected increased upregulation of proinflammatory cytokine/chemokine transcript levels in immunized mice, which most likely was a downstream effect of STAT3 activation. This upregulation was diminished by nicotine treatment and corresponding downregulation of IL-6. The downregulation of IL-6 appears to play a central role in the reduction of proinflammatory chemokines, because STAT3 activation through JAK2 is mediated by binding of IL-6 to its corresponding receptor. 52 To highlight the crucial role of IL-6 in the molecular pathophysiology of the cholinergic antiinflammatory pathway, we administered IL-6 concomitantly with nicotine in TnI-immunized mice. IL-6 treatment reversed the antiinflammatory effect of nicotine treatment, as shown by the milder disease outcome. We therefore suppose that binding of nicotine to ␣7-nAChR on specific immune cells leads to decreased IL-6 production (mostly by CD3 ϩ CD4 ϩ cells), which in turn reduces activation of STAT3. Chemokine expression, which is a downstream process of STAT3, is thereby inhibited on nicotine administration. In the present study, nicotine treatment resulted in downregulation of the chemokines RANTES, MIP-1␤, and MCP-1 and the chemokine receptors CCR1, CCR2, and CCR5.
Together, these results show that activation of the cholinergic antiinflammatory pathway via nicotine stimulation reduces inflammation in TnI-induced autoimmune myocarditis. To date, there is no specific treatment for myocarditis. Therapy is symptomatic and restricted to standard heart failure medication (eg, ACE inhibitors, angiotensin receptor blockers, ␤-blockers, and diuretics) and implantable cardiac defibrillators or, ultimately, cardiac transplantation. Because cytokine imbalance plays a major role in myocarditis, the targeting of proinflammatory cytokines such as TNF-␣ or IL-6 might be a promising option. Nevertheless, clinical trials using biologics such as infliximab (monoclonal anti-TNF-␣ antibodies) failed to show a benefit for patients with dilated cardiomyopathy with an autoimmune cause. Thus, novel methods should be established to influence cytokine balance to reduce proinflammatory mediators. The present study clearly shows that activation of the efferent vagus has potential for clinical implementation in the future; however, we cannot exclude the possibility that chronic nicotine stimulation may lead to nicotine tolerance, which may influence cytokine balance. Hence, further studies are needed to elucidate whether nicotine stimulation may be used in a clinical setting to treat autoimmune myocarditis.
